These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance. Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548 [TBL] [Abstract][Full Text] [Related]
4. Conventional MR-based Preoperative Nomograms for Prediction of IDH/1p19q Subtype in Low-Grade Glioma. Liu Z; Zhang T; Jiang H; Xu W; Zhang J Acad Radiol; 2019 Aug; 26(8):1062-1070. PubMed ID: 30393056 [TBL] [Abstract][Full Text] [Related]
5. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign. Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467 [TBL] [Abstract][Full Text] [Related]
6. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas. Paul Y; Mondal B; Patil V; Somasundaram K Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842 [TBL] [Abstract][Full Text] [Related]
8. An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. Gittleman H; Lim D; Kattan MW; Chakravarti A; Gilbert MR; Lassman AB; Lo SS; Machtay M; Sloan AE; Sulman EP; Tian D; Vogelbaum MA; Wang TJC; Penas-Prado M; Youssef E; Blumenthal DT; Zhang P; Mehta MP; Barnholtz-Sloan JS Neuro Oncol; 2017 May; 19(5):669-677. PubMed ID: 28453749 [TBL] [Abstract][Full Text] [Related]
9. Development and validation of a novel survival prediction model for newly diagnosed lower-grade gliomas. Zhu Q; Liang Y; Fan Z; Liu Y; Zhou C; Zhang H; He L; Li T; Yang J; Zhou Y; Wang J; Wang L Neurosurg Focus; 2022 Apr; 52(4):E13. PubMed ID: 35364578 [TBL] [Abstract][Full Text] [Related]
10. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients. Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941 [TBL] [Abstract][Full Text] [Related]
11. Combining hyperintense FLAIR rim and radiological features in identifying IDH mutant 1p/19q non-codeleted lower-grade glioma. Li M; Ren X; Chen X; Wang J; Shen S; Jiang H; Yang C; Zhao X; Zhu Q; Cui Y; Lin S Eur Radiol; 2022 Jun; 32(6):3869-3879. PubMed ID: 35079884 [TBL] [Abstract][Full Text] [Related]
12. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas. Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009 [TBL] [Abstract][Full Text] [Related]
14. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma. Karsy M; Guan J; Huang LE J Neurosurg; 2019 Jan; 130(1):56-66. PubMed ID: 29547090 [TBL] [Abstract][Full Text] [Related]
15. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion. Chen SC; Lo CM; Wang SH; Su EC BMC Bioinformatics; 2019 Dec; 20(Suppl 19):659. PubMed ID: 31870275 [TBL] [Abstract][Full Text] [Related]
16. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas. Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286 [TBL] [Abstract][Full Text] [Related]
17. An autophagic gene-based signature to predict the survival of patients with low-grade gliomas. Chen J; Li Y; Han X; Pan Y; Qian X Cancer Med; 2021 Mar; 10(5):1848-1859. PubMed ID: 33591634 [TBL] [Abstract][Full Text] [Related]
18. A 1p/19q Codeletion-Associated Immune Signature for Predicting Lower Grade Glioma Prognosis. Xu J; Liu F; Li Y; Shen L Cell Mol Neurobiol; 2022 Apr; 42(3):709-722. PubMed ID: 32894375 [TBL] [Abstract][Full Text] [Related]
19. Mathematical Modeling and Mutational Analysis Reveal Optimal Therapy to Prevent Malignant Transformation in Grade II IDH-Mutant Gliomas. Aoki K; Suzuki H; Yamamoto T; Yamamoto KN; Maeda S; Okuno Y; Ranjit M; Motomura K; Ohka F; Tanahashi K; Hirano M; Nishikawa T; Shimizu H; Kitano Y; Yamaguchi J; Yamazaki S; Nakamura H; Takahashi M; Narita Y; Nakada M; Deguchi S; Mizoguchi M; Momii Y; Muragaki Y; Abe T; Akimoto J; Wakabayashi T; Saito R; Ogawa S; Haeno H; Natsume A Cancer Res; 2021 Sep; 81(18):4861-4873. PubMed ID: 34333454 [TBL] [Abstract][Full Text] [Related]
20. Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in Batchala PP; Muttikkal TJE; Donahue JH; Patrie JT; Schiff D; Fadul CE; Mrachek EK; Lopes MB; Jain R; Patel SH AJNR Am J Neuroradiol; 2019 Mar; 40(3):426-432. PubMed ID: 30705071 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]